News Medical29d
FasL inhibitor speeds recovery and reduces mortality in severe COVID-19 patients
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight ...
EurekAlert!1mon
New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight ...
Medical Xpress29d
Therapeutic approach to treat virus-induced lung failure for severe COVID-19 shows promise in clinical trial
A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality. On average, it took eight ...
Nature10y
Fas counter-attack–the best form of tumor defense?
A recent report demonstrated that murine AK-5 tumor cells transiently upregulated FasL when grown in the peritoneal cavity of syngeneic mice, and that this FasL upregulation coincided with ...
Nature10d
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by ...